Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with
PD-1 antibody compared with lenvtinib Alone in patients with advanced hepatocellular
carcinoma (HCC)
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Guangzhou No.12 People's Hospital Kaiping Central Hospital The First Affiliated Hospital of University of South China